MyoKardia

YTD

ALL

Why Robinhood?

You can watch MyoKardia and buy or sell other stocks, ETFs, and their options commission-free!

About MYOK

MyoKardia, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, commercialization, and development of therapies for the treatment of cardiovascular diseases. Its lead therapeutic candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin being developed for the treatment of hypertrophic cardiomyopathy (HCM).

CEO

Sandra Ramos-Alves

CEOSandra Ramos-Alves

Employees

—

Employees—

Headquarters

Brisbane, California

HeadquartersBrisbane, California

Founded

2012

Founded2012

Employees

—

Employees—

MYOK Key Statistics

Market cap

11.99B

Market cap11.99B

Price-Earnings ratio

-39.87

Price-Earnings ratio-39.87

Dividend yield

—

Dividend yield—

Average volume

1.31M

Average volume1.31M

High today

—

High today—

Low today

—

Low today—

Open price

—

Open price—

Volume

0.00

Volume0.00

52 Week high

$225.00

52 Week high$225.00

52 Week low

$42.65

52 Week low$42.65

People also own

Based on the portfolios of people who own MYOK. This list is generated using Robinhood data, and it’s not a recommendation.